Literature DB >> 12187250

Histology of upper pole is unaffected by prenatal diagnosis in duplex system ureteroceles.

Stephane Bolduc, Jyoti Upadhyay, Christopher Sherman, Walid Farhat, Darius J Bagli, Gordon A McLorie, Antoine E Khoury, Alaa El-Ghoneimi.   

Abstract

PURPOSE: We determined whether the histology of upper pole nephrectomy specimens vary with prenatal detection or ureterocele position.
MATERIALS AND METHODS: Between 1992 and 2000, 95 patients with ureteroceles associated with a duplex system underwent surgical interventions, including upper pole nephrectomy in 60. A total of 55 specimens, of which 25 and 30 involved a prenatal and postnatal diagnosis, and 18 and 37 involved an intravesical and extravesical location, respectively, were available for independent review by a single pathologist. Histological lesions were classified into the 5 categories of chronic interstitial inflammation, fibrosis, tubular atrophy, glomerulosclerosis and dysplasia. Each category was divided into moderate/severe histological lesions (greater than 25% involvement) and minimal/mild lesions (25% or less involvement).
RESULTS: A moderate/severe histological lesion was identified in 38 patients (69%) and a minimal/mild lesion was detected in 17 (31%), while dysplasia was present in 35 (64%). There was no significant difference in histological lesions and mode of presentation. In contrast to intravesical ureteroceles, extravesical ureteroceles were associated with severe fibrosis and tubular atrophy (p <0.05). Chronic interstitial inflammation, fibrosis, tubular atrophy and glomerulosclerosis in each specimen were graded moderate/severe (greater than 25% involved) in 55%, 67%, 66% and 53%, respectively.
CONCLUSIONS: Prenatally diagnosed ureteroceles were not associated with less severe upper pole histological lesions. We noted pathological differences when comparing specimens according to ureterocele position, but chronic inflammation and dysplasia were similar in intravesical and extravesical ureterocele cases. It appears that the histological lesions observed are not progressive or reversible. Therefore, the goals of clinical management should focus on providing adequate drainage, antibiotic prophylaxis coverage and followup of reflux rather than the preservation or enhancement of upper pole function.

Entities:  

Mesh:

Year:  2002        PMID: 12187250     DOI: 10.1097/01.ju.0000025866.15856.0f

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Obstructive ureterocele-an ongoing challenge.

Authors:  E Merlini; P Lelli Chiesa
Journal:  World J Urol       Date:  2004-06-15       Impact factor: 4.226

Review 2.  Upper Pole Heminephrectomy Versus Lower Pole Ureteroureterostomy for Ectopic Upper Pole Ureters.

Authors:  Jason E Michaud; Ardavan Akhavan
Journal:  Curr Urol Rep       Date:  2017-03       Impact factor: 3.092

3.  Clinico-pathological correlation in duplex system ectopic ureters and ureteroceles: can preoperative work-up predict renal histology?

Authors:  Davide Meneghesso; Marco Castagnetti; Manuela Della Vella; Elisa Benetti; Pietro Zucchetta; Waifro Rigamonti; Luisa Murer
Journal:  Pediatr Surg Int       Date:  2011-11-30       Impact factor: 1.827

Review 4.  Management of duplex system ureteroceles in neonates and infants.

Authors:  Marco Castagnetti; Alaa El-Ghoneimi
Journal:  Nat Rev Urol       Date:  2009-06       Impact factor: 14.432

5.  Long-term functional renal outcomes after retroperitoneoscopic upper pole heminephrectomy for duplex kidney in children: a multicenter cohort study.

Authors:  Luc Joyeux; Isabelle Lacreuse; Anne Schneider; Raphael Moog; Josephine Borgnon; Manuel Lopez; François Varlet; François Becmeur; Emmanuel Sapin
Journal:  Surg Endosc       Date:  2016-07-15       Impact factor: 4.584

6.  Pediatric ureteroceles: diagnosis, management and treatment options.

Authors:  Cüneyt Günşar; Erol Mir; Aydin Sencan; Pelin Ertan; Cansu Ünden Ozcan
Journal:  Iran J Pediatr       Date:  2010-12       Impact factor: 0.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.